...
search icon
knsa-img

Kiniksa Pharmaceuticals Ltd, Common Stock

KNSA

NSQ

$21.365

+$0.8

(3.89%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$1.46B
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
415.96K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.31
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$17.38 L
$28.15 H
$21.365

About Kiniksa Pharmaceuticals Ltd, Common Stock

Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, developing and commercializing novel therapies for diseases with unmet need and focuses on cardiovascular indications worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-387, an investigational, that is in Phase 2/3 clinical trial for human immunoglobulin G2 monoclonal antibody that binds human interleukin-1 receptor 1, inhibiting IL-1a, IL-1ß-mediated signaling for the treatment of advance recurrent pericarditis by providing the added convenience of monthly subcutaneous dosing with a liquid formulation. Its preclinical products include KPL-116, a Fc-modified immunoglobulin G2 monoclonal antibody. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameKNSASectorS&P500
1-Week Return6.56%3.64%6.36%
1-Month Return-7.87%-5.42%-5.32%
3-Month Return2.91%-6.89%-8.86%
6-Month Return-22.14%-7.54%-5.61%
1-Year Return21.32%-1.81%8.61%
3-Year Return109.87%2.1%27.58%
5-Year Return1.74%35.25%90.38%
10-Year Return9.73%88.1%160.03%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue7.70M38.54M220.18M270.26M423.24M[{"date":"2020-12-31","value":1.82,"profit":true},{"date":"2021-12-31","value":9.11,"profit":true},{"date":"2022-12-31","value":52.02,"profit":true},{"date":"2023-12-31","value":63.85,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue3.81M9.10M46.97M56.52M60.91M[{"date":"2020-12-31","value":6.25,"profit":true},{"date":"2021-12-31","value":14.94,"profit":true},{"date":"2022-12-31","value":77.11,"profit":true},{"date":"2023-12-31","value":92.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit(3.81M)29.44M173.21M213.74M423.24M[{"date":"2020-12-31","value":-0.9,"profit":false},{"date":"2021-12-31","value":6.96,"profit":true},{"date":"2022-12-31","value":40.93,"profit":true},{"date":"2023-12-31","value":50.5,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Margin(49.39%)76.39%78.67%79.09%100.00%[{"date":"2020-12-31","value":-49.39,"profit":false},{"date":"2021-12-31","value":76.39,"profit":true},{"date":"2022-12-31","value":78.67,"profit":true},{"date":"2023-12-31","value":79.09,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Expenses157.36M186.08M163.44M238.93M468.86M[{"date":"2020-12-31","value":33.56,"profit":true},{"date":"2021-12-31","value":39.69,"profit":true},{"date":"2022-12-31","value":34.86,"profit":true},{"date":"2023-12-31","value":50.96,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Operating Income(157.36M)(156.64M)7.37M(25.20M)(45.62M)[{"date":"2020-12-31","value":-2134.89,"profit":false},{"date":"2021-12-31","value":-2125.03,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-341.83,"profit":false},{"date":"2024-12-31","value":-618.86,"profit":false}]
Total Non-Operating Income/Expense2.27M194.00K2.51M--[{"date":"2020-12-31","value":90.5,"profit":true},{"date":"2021-12-31","value":7.74,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Pre-Tax Income(156.23M)(156.54M)11.03M(16.65M)(36.15M)[{"date":"2020-12-31","value":-1416.91,"profit":false},{"date":"2021-12-31","value":-1419.73,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-151.02,"profit":false},{"date":"2024-12-31","value":-327.88,"profit":false}]
Income Taxes5.15M1.39M(172.34M)(30.74M)7.04M[{"date":"2020-12-31","value":73.17,"profit":true},{"date":"2021-12-31","value":19.67,"profit":true},{"date":"2022-12-31","value":-2447.62,"profit":false},{"date":"2023-12-31","value":-436.53,"profit":false},{"date":"2024-12-31","value":100,"profit":true}]
Income After Taxes(161.38M)(157.92M)183.36M--[{"date":"2020-12-31","value":-88.01,"profit":false},{"date":"2021-12-31","value":-86.13,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(161.38M)(157.92M)183.36M(6.69M)(43.19M)[{"date":"2020-12-31","value":-88.01,"profit":false},{"date":"2021-12-31","value":-86.13,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":-3.65,"profit":false},{"date":"2024-12-31","value":-23.56,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(161.38M)(157.92M)183.36M14.08M(43.19M)[{"date":"2020-12-31","value":-88.01,"profit":false},{"date":"2021-12-31","value":-86.13,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":7.68,"profit":true},{"date":"2024-12-31","value":-23.56,"profit":false}]
EPS (Diluted)(2.58)(2.30)2.590.18(0.61)[{"date":"2020-12-31","value":-99.61,"profit":false},{"date":"2021-12-31","value":-88.8,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":6.95,"profit":true},{"date":"2024-12-31","value":-23.55,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

KNSA
Cash Ratio 2.42
Current Ratio 3.30
Quick Ratio 3.04

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

KNSA
ROA (LTM) -5.15%
ROE (LTM) -9.85%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

KNSA
Debt Ratio Lower is generally better. Negative is bad. 0.24
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.76

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

KNSA
Trailing PE NM
Forward PE NM
P/S (TTM) 3.68
P/B 3.41
Price/FCF 84
EV/R 2.98
EV/Ebitda NM

FAQs

What is Kiniksa Pharmaceuticals Ltd share price today?

Kiniksa Pharmaceuticals Ltd (KNSA) share price today is $21.365

Can Indians buy Kiniksa Pharmaceuticals Ltd shares?

Yes, Indians can buy shares of Kiniksa Pharmaceuticals Ltd (KNSA) on Vested. To buy Kiniksa Pharmaceuticals Ltd from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in KNSA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Kiniksa Pharmaceuticals Ltd be purchased?

Yes, you can purchase fractional shares of Kiniksa Pharmaceuticals Ltd (KNSA) via the Vested app. You can start investing in Kiniksa Pharmaceuticals Ltd (KNSA) with a minimum investment of $1.

How to invest in Kiniksa Pharmaceuticals Ltd shares from India?

You can invest in shares of Kiniksa Pharmaceuticals Ltd (KNSA) via Vested in three simple steps:

  • Click on Sign Up or Invest in KNSA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Kiniksa Pharmaceuticals Ltd shares
What is Kiniksa Pharmaceuticals Ltd 52-week high and low stock price?

The 52-week high price of Kiniksa Pharmaceuticals Ltd (KNSA) is $28.15. The 52-week low price of Kiniksa Pharmaceuticals Ltd (KNSA) is $17.38.

What is Kiniksa Pharmaceuticals Ltd price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Kiniksa Pharmaceuticals Ltd (KNSA) is 3.41

What is the Market Cap of Kiniksa Pharmaceuticals Ltd?

The market capitalization of Kiniksa Pharmaceuticals Ltd (KNSA) is $1.46B

What is Kiniksa Pharmaceuticals Ltd’s stock symbol?

The stock symbol (or ticker) of Kiniksa Pharmaceuticals Ltd is KNSA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top